Cornerstone Capital Inc. lessened its stake in Amgen Inc. (NASDAQ:AMGN – Free Report) by 1.9% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 89,199 shares of the medical research company’s stock after selling 1,725 shares during the quarter. Amgen comprises about 3.3% of Cornerstone Capital Inc.’s holdings, making the stock its 10th largest holding. Cornerstone Capital Inc.’s holdings in Amgen were worth $37,598,000 as of its most recent filing with the SEC.
A number of other institutional investors have also recently added to or reduced their stakes in the stock. Quest 10 Wealth Builders Inc. boosted its stake in Amgen by 220.0% during the third quarter. Quest 10 Wealth Builders Inc. now owns 80 shares of the medical research company’s stock worth $34,000 after buying an additional 55 shares during the last quarter. Wellington Altus USA Inc. grew its holdings in Amgen by 72.3% in the 2nd quarter. Wellington Altus USA Inc. now owns 81 shares of the medical research company’s stock valued at $28,000 after buying an additional 34 shares in the last quarter. Nvwm LLC increased its stake in shares of Amgen by 412.5% in the 3rd quarter. Nvwm LLC now owns 82 shares of the medical research company’s stock worth $35,000 after acquiring an additional 66 shares during the last quarter. PFS Partners LLC increased its stake in shares of Amgen by 95.5% in the 3rd quarter. PFS Partners LLC now owns 86 shares of the medical research company’s stock worth $36,000 after acquiring an additional 42 shares during the last quarter. Finally, TOWER TRUST & INVESTMENT Co acquired a new stake in shares of Amgen in the 3rd quarter worth $38,000. Hedge funds and other institutional investors own 76.50% of the company’s stock.
Wall Street Analyst Weigh In
Several research firms have recently commented on AMGN. Citigroup lifted their price target on Amgen from $405.00 to $465.00 and gave the stock a “neutral” rating in a report on Wednesday, November 4th. Robert W. Baird upped their price objective on shares of Amgen from $215.00 to $230.00 and gave the company an “underperform” rating in a report on Wednesday, August 5th. Royal Bank Of Canada raised their price objective on shares of Amgen from $430.00 to $470.00 and gave the stock an “outperform” rating in a research report on Wednesday, November 4th. Mizuho raised their price objective on shares of Amgen from $303.00 to $352.00 and gave the stock a “neutral” rating in a research report on Tuesday, August 18th. Finally, Guggenheim lifted their target price on shares of Amgen from $378.00 to $435.00 and gave the stock a “neutral” rating in a research note on Thursday, November 5th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, eighteen have issued a Hold rating and three have assigned a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $425.69.
Amgen Trading Down 0.7%
Shares of Amgen stock opened at $462.32 on Tuesday. The stock has a 50 day moving average of $425.81 and a 200 day moving average of $381.77. The company has a debt-to-equity ratio of 3.60, a quick ratio of 1.20 and a current ratio of 1.48. The firm has a market capitalization of $250.07 billion, a price-to-earnings ratio of 26.82, a PEG ratio of 3.25 and a beta of 0.43. Amgen Inc. has a fifty-two week low of $312.39 and a fifty-two week high of $483.99.
Amgen (NASDAQ:AMGN – Get Free Report) last posted its earnings results on Tuesday, November 3rd. The medical research company reported $6.45 EPS for the quarter, beating analysts’ consensus estimates of $5.79 by $0.66. Amgen had a return on equity of 114.99% and a net margin of 24.14%. The company had revenue of $10.37 billion for the quarter, compared to the consensus estimate of $10.07 billion. During the same quarter in the previous year, the business earned $5.64 earnings per share. The company’s revenue for the quarter was up 8.5% on a year-over-year basis. As a group, research analysts predict that Amgen Inc. will post 23.37 earnings per share for the current year.
Amgen Announces Dividend
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, December 11th. Investors of record on Friday, November 20th will be given a dividend of $2.52 per share. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.2%. The ex-dividend date of this dividend is Friday, November 20th. Amgen’s dividend payout ratio (DPR) is presently 58.47%.
Amgen Profile
Amgen is a biotechnology company that discovers, develops, manufactures and commercializes medicines for serious illnesses. Its research and product portfolio span areas including cancer, cardiovascular disease, inflammation, bone health and rare diseases. The company’s medicines include Enbrel, Prolia, Xgeva and Repatha. Amgen serves patients and healthcare providers in the United States and markets its products internationally. Founded in 1980 and headquartered in Thousand Oaks, California, Amgen is led by Robert A. Bradway, who has served as its chief executive officer since 2012.
Recommended Stories
- Five stocks we like better than Amgen
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.
